Literature DB >> 21788973

Targeted therapies: Improved outcomes for patients with metastatic melanoma.

Vernon K Sondak1, Lawrence E Flaherty.   

Abstract

Recently published phase III trials involving interleukin-2, ipilimumab and vemurafenib redefine 'standard-of-care' for metastatic melanoma and demonstrate improved survival compared with dacarbazine. All three therapies are potential first-line options for patients with metastatic melanoma, with optimal treatment strategies evolving based on tumor mutation status, disease burden, performance status and comorbidities.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21788973     DOI： 10.1038/nrclinonc.2011.119

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Authors:  Douglas J Schwartzentruber; David H Lawson; Jon M Richards; Robert M Conry; Donald M Miller; Jonathan Treisman; Fawaz Gailani; Lee Riley; Kevin Conlon; Barbara Pockaj; Kari L Kendra; Richard L White; Rene Gonzalez; Timothy M Kuzel; Brendan Curti; Phillip D Leming; Eric D Whitman; Jai Balkissoon; Douglas S Reintgen; Howard Kaufman; Francesco M Marincola; Maria J Merino; Steven A Rosenberg; Peter Choyke; Don Vena; Patrick Hwu
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

3.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

4.  Melanoma--an unlikely poster child for personalized cancer therapy.

Authors:  Keiran S M Smalley; Vernon K Sondak
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 6.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  The histologic spectrum of epithelial neoplasms induced by sorafenib.

Authors:  Eun Ji Kwon; L Stephen Kish; Christine Jaworsky
Journal:  J Am Acad Dermatol       Date:  2009-09       Impact factor: 11.527

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 9.  Systematic review of medical treatment in melanoma: current status and future prospects.

Authors:  Claus Garbe; Thomas K Eigentler; Ulrich Keilholz; Axel Hauschild; John M Kirkwood
Journal:  Oncologist       Date:  2011-01-06
  9 in total
  6 in total

1.  Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.

Authors:  Mark E McDonnell; Matthew D Vera; Benjamin E Blass; Jeffrey C Pelletier; Richard C King; Carmen Fernandez-Metzler; Garry R Smith; Jay Wrobel; Suzie Chen; Brian A Wall; Allen B Reitz
Journal:  Bioorg Med Chem       Date:  2012-07-21       Impact factor: 3.641

Review 2.  Therapeutic antibodies against cancer.

Authors:  Mark J Adler; Dimiter S Dimitrov
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

3.  Dipeptide Prodrugs of the Glutamate Modulator Riluzole.

Authors:  Jeffrey C Pelletier; Suzie Chen; Haiyan Bian; Raj Shah; Garry R Smith; Jay E Wrobel; Allen B Reitz
Journal:  ACS Med Chem Lett       Date:  2018-06-15       Impact factor: 4.345

Review 4.  Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.

Authors:  Mengdong Liu; Xuekang Yang; Jiaqi Liu; Bin Zhao; Weixia Cai; Yan Li; Dahai Hu
Journal:  Oncotarget       Date:  2017-05-09

5.  Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.

Authors:  Marija Dorđić; Ivana Z Matić; Ivana Filipović-Lješković; Radan Džodić; Miomir Sašić; Aleksandra Erić-Nikolić; Ana Vuletić; Branka Kolundžija; Ana Damjanović; Nađa Grozdanić; Srđan Nikolić; Janko Pralica; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Zorica Juranić
Journal:  BMC Complement Altern Med       Date:  2012-07-26       Impact factor: 3.659

6.  Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

Authors:  Cecilia Lezcano; Chung-Wei Lee; Allison R Larson; Alexander M Menzies; Richard F Kefford; John F Thompson; Martin C Mihm; Shuji Ogino; Georgina V Long; Richard A Scolyer; George F Murphy
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.